Calcium channel blockers for primary Raynaud's phenomenon: A meta-analysis

Rheumatology

Volumn 44, Issue 2, 2005, Pages 145-150

  Thompson, A E ^b   Pope, J E ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DAZOXIBEN; DILTIAZEM; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; PLACEBO;

CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; EDEMA; FLUSHING; HEADACHE; HUMAN; HYPOTENSION; ISCHEMIA; MEDLINE; META ANALYSIS; MONOTHERAPY; MORBIDITY; PRIORITY JOURNAL; RANDOMIZATION; RAYNAUD PHENOMENON; REVIEW; SCISEARCH; SIDE EFFECT; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

CALCIUM CHANNEL BLOCKERS; HUMANS; ISCHEMIA; NIFEDIPINE; RANDOMIZED CONTROLLED TRIALS; RAYNAUD DISEASE; TREATMENT OUTCOME;

EID: 14044261363     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh390     Document Type: Review

References (38)

1. Nilsson H, Jonason T, Leppert J, Ringqvist I. The effect of the calcium-entry blocker nifedipine on cold-induced digital vasospasm. A double-blind crossover study versus placebo. Acta Med Scand 1987;221:53-60.
2. Sarkozi J, Bookman A, Mahon W, Ramsay C, Detsky AS, Keystone EC. Nifedipine in the treatment of idiopathic Raynaud's syndrome. J Rheumatol 1986;13:331-6.
3. Corbin DO, Wood DA, Macintyre CC, Housley E. A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon. Eur Heart J 1986;7:165-70.
4. Gjorup T, Kelbaek H, Hartling OJ, Nielsen SL. Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenon. Am Heart J 1986;111:742-5.
5. Waller DG, Challenor VF, Francis DA, Roath OS. Clinical and theological effects of nifedipine in Raynaud's phenomenon. Br J Clin Pharmacol 1986;22:449-54.
6. Rodeheffer RJ, Rommer JA, Wigley F, Smith CR. Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon. N Engl J Med 1983;308:880-3.
7. Raynaud's Treatment Study Investigators. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow-up. Arch Intern Med 2000;160:1101-8.
8. Challenor VF, Waller DG, Hayward RA, Griffin MJ, Roath OS. Vibrotactile sensation and response to nifedipine dose titration in primary Raynaud's phenomenon. Angiology 1989;40:122-8.
9. Rivera, RJ, Noguerdo AA, Lopez BJP et al. Nifedipine treatment of Raynaud's phenomenon: A double-blind controlled clinical study. [Spanish]. Rev Esp Reumatol 1986;13:121-3.
10. Dziadzio M, Denton CP, Smith R et al. Losartan therapy for Raynaud's phenomenon and scleroderma. Arthritis Rheum 1999; 42:2646-55.
11. Kahan A, Weber S, Amor B et al. Etude controlée de la nifedipine dans la traitement du phénomène de raynaud. Rev Rhum Mal Osteoarth 1982;49:337-47.
12. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. Br Med J 1994;309:1286-91.
13. Jadad A, Moore A, Carrol D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
14. Petitti D. Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine. New York: Oxford University Press, 1994:90-114.
15. Hawkins SJ, Black CM, Hall ND, McGregor A, Ring EF, Maddison PJ. Clinical and laboratory effects of nifedipine in Raynaud's phenomenon. Rheumatol Int 1986;6:85-8.
16. Creager MA, Pariser KM, Winston EM, Rasmussen HM, Miller KB, Coffman JD. Nifedipine-induced fingertip vasodilation in patients with Raynaud's phenomenon. Am Heart J 1984;108:370-3.
17. White CJ, Phillips WA, Abrahams LA, Watson TD, Singleton PT Jr. Objective benefit of nifedipine in the treatment of Raynaud's phenomenon. Double-blind controlled study. Am J Med 1986;80: 623-5.
18. Sauza J, Kraus A, Gonsalez-Amaro R, Alarcon-Segovia D. Effect of the calcium channel blocker nifedipine on Raynaud's phenomenon. A controlled double blind trial. J Rheumatol 1984;11:362-4.
19. Kallenberg CG, Wouda AA, Meems L, Wesseling H. Once daily felodipine in patients with primary Raynaud's phenomenon. Eur J Clin Pharmacol 1991;40:313-5.
20. La Civita L, Pitaro N, Rossi M et al. Amlodipine in the treatment of Raynaud's phenomenon. Br J Rheumatol 1993;32:524-5.
21. Rhedda A, McCans J, Willan AR, Ford PM. A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon. J Rheumatol 1985;12:724-7.
22. Wollersheim H, Thien T. Double-blind placebo-controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. J Cardiovasc Pharmacol 1991;18:813-8.
23. Wigley FM, Wise RA, Malamet R, Scott TE. Nicardipine in the treatment of Raynaud's phenomenon. Dissociation of platelet activation from vasospasm. Arthritis Rheum 1987;30:281-6.
24. Ferri C, Cecchetti R, Cini G et al. Slow-releasing nicardipine in the treatment of Raynaud's phenomena without underlying diseases. Clin Rheumatol 1992;11:76-80.
25. Kallenberg CG, Wouda AA, Kuitert JJ, Tijssen J, Wesseling H. Nifedipine in Raynaud's phenomenon: relationship between immediate, short term and long term effects. J Rheumatol 1987;14: 284-90.
26. Wollersheim H, Thien T, van't Laar A. Nifedipine in primary Raynaud's phenomenon and in scleroderma: oral versus sublingual hemodynamic effects. J Clin Pharmacol 1987;27:907-13.
27. Aldoori M, Campbell WB, Dieppe PA. Nifedipine in the treatment of Raynaud's syndrome. Cardiovasc Res 1986;20:466-70.
28. Kahan A, Weber S, Amor B et al. Calcium entry blocking agents in digital vasospasm (Raynaud's phenomenon). Eur Heart J 1983; 4 Suppl.:123-9.
29. Redondo FR, Noguerado A, Asensio JP, Bote L, Alvaro-Gracia JM, Castellanos O. Tratamiento del fenomeno de Raynaud con nifedipina. Un studio controlado a doble ciego. Rev Esp Reumatol 1986;13: 121-3.
30. Ettinger WH, Wise RA, Schaffhauser RN, Wigley FM. Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. Am J Med 1984;77:451-6.
31. Kahan A, Foult JM, Weber S, Amor B, Menkes CJ, Degeorges M. Nifedipine and alpha-1-adrenergic blockade in Raynaud's phenomenon. Eur Heart J 1985;6:702-5.
32. Kahan A, Amor B, Menkes CJ. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon. Ann Rheum Dis 1985;44:30-3.
33. Challenor VF, Waller DG, Francis DA, Francis JL, Mani R, Roath S. Nisoldipine in primary Raynaud's phenomenon. Eur J Clin Pharmacol 1987;33:27-30.
34. Gjorup T, Hartling OJ, Kelbaek H, Nielsen SL. Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon. Eur J Clin Pharmacol 1986;31:387-9.
35. Kahan A, Amor B, Menkes CJ, Weber S, Guerin F, Degeorges M. Nicardipine in the treatment of Raynaud's phenomenon: a randomized double-blind trial. Angiology 1987;38:333-7.
36. French Cooperative Multicenter Group for Raynaud Phenomenon. Controlled multicenter double-blind trial of nicardipine in the treatment of primary Raynaud phenomenon. Am Heart J 1991;122: 352-5.
37. Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001;44:1841-7.
38. Weber A, Bounameaux H. Effects of low-dose nifedipine on a cold provocation test in people with Raynaud's disease. J Cardiovasc Pharmacol 1990;15:853-5.